Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement

Multiple Myeloma Clinical Trial

— SPODUMENE  

Official title:

A Phase 2 Study of Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With Central Nervous System Involvement

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05478993
• Other study ID #: 01/20/2022
• Status: Recruiting
• Phase: Phase 2
• Start date: October 12, 2022
• Est. completion date: July 10, 2025

Study information

• Verified date: January 2024
• Source: Peking University People's Hospital
• Contact: Xuelin Dou, M.D.
• Phone: +86-010-82816999
• Email: dxldw[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-arm, open-label, multicenter, exploratory study initiated by investigator to evaluate the efficacy and safety of Selinexor (S) combined with pomalidomide (P) and dexamethasone (D) in the treatment of multiple myeloma with CNS involvement.

Description:

This is a single-arm, open-label, multicenter, exploratory study. The study plans to enroll patients diagnosed with multiple myeloma with CNS involvement to receive Selinexor (60 mg QW), pomalidomide (4 mg/day, on Days 1-21), and dexamethasone (40 mg/day, on Days 1, 8, 15, 22), with all agents dosed 28 days per cycle.

If patients reach maximum efficacy and have received SPD treatment for 8-12 cycles, maintenance treatment of Selinexor (20-60mg QW, optimal dose determined by the investigator) will be started and continued until disease progression or intolerable adverse events.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 21
• Est. completion date: July 10, 2025
• Est. primary completion date: July 10, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years.

2. Patients with multiple myeloma with measurable lesions as assessed using the updated International Myeloma Working Group Response Criteria.

3. Multiple myeloma patients with central nervous system involvement (CNS-MM): the presence of plasma cells in the cerebrospinal fluid (CSF), and/or leptomeningeal, dural, or intraparenchymal involvement as assessed using imaging modalities (MRI, CT or PET-CT), and/or tissue biopsy; or eye involvement confirmed by ophthalmologists, with or without neurological symptoms.

4. ECOG = 2, with expected survival of more than 3 months.

5. No active infectious diseases.

6. Major organs without serious organic diseases (except renal insufficiency caused by multiple myeloma).

7. Female patients are not during pregnancy or breastfeeding; fertile men or women agree to use appropriate methods of contraception 4 weeks before study treatment, during treatment and drug suspension, and within 4 weeks after the end of study treatment.

8. Be able to cooperate with study follow-up. Patients understand the disease characteristics and voluntarily join this study to receive treatments and study follow-ups.

9. Have signed informed consent. Informed consent was signed by the patient or by an immediate family member. Considering the patient 's condition, if the patient' s signature is unfavorable for disease treatment, the informed consent form should be signed by the legal guardian or the patient 's immediate family member.

Exclusion Criteria:

1. Patients with active hepatitis B (HBV), hepatitis C (HCV), and other acquired, congenital immunodeficiency diseases;

2. According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) 5.0, baseline with grade 2 or higher peripheral neuropathy or neuralgia;

3. Severe thrombotic events before treatment;

4. Patients with uncontrolled or severe cardiovascular disease, including myocardial infarction within 6 months before enrollment, New York Heart Association (NYHA) defined grade III-IV heart failure, uncontrolled angina pectoris, clinically significant pericardial disease or cardiac amyloidosis;

5. Major surgery within 30 days before enrollment;

6. Epilepsy and dementia which requires drug treatment, and other mental disorders which cannot understand or follow the study protocol;

7. According to the protocol or the investigator 's judgment, any severe physical illness or mental illness may interfere with participation in this clinical study;

8. Drug abuse, medical, psychological or social conditions that may interfere with the participation of subjects in the study or evaluation of study results;

9. Patients who are receiving other experimental treatment;

10. Pregnant or lactating women;

11. Not suitable for enrollment per investigators' judgements.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• SPD:Selinexor Oral Tablet, Pomalidomide, Dexamethasone
Patients diagnosed with multiple myeloma with CNS involvement to receive Selinexor (60 mg QW), pomalidomide (4 mg/day, on Days 1-21), and dexamethasone (40 mg/day, on Days 1, 8, 15, 22), with all agents dosed 28 days per cycle. If patients reach maximum efficacy and have received SPD treatment for 8-12 cycles, maintenance treatment of Selinexor (20-60mg QW, optimal dose determined by the investigator) will be started and continued until disease progression or intolerable adverse events.

Locations

Country	Name	City	State
China	Peking University People's Hospital	Beijing	Beijing
China	Qingdao Municipal Hospital	Qingdao	Shandong

Sponsors (2)

Lead Sponsor	Collaborator
Peking University People's Hospital	Qingdao Municipal Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival	Assessed using the updated International Myeloma Working Group Response Criteria	From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
Secondary	Overall survival	Assessed using the updated International Myeloma Working Group Response Criteria	From date of enrollment until date of death from any cause, assessed up to 24 months.
Secondary	Overall response rate	Assessed using the updated International Myeloma Working Group Response Criteria	From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
Secondary	Adverse Events	Assessed using the CTCAE criteria.	From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.